2016 Distinguished Pharmacy Alumni Awardee
Terry L. Holcslaw
Vice President of Business Development
New Drug Development Services, Inc.
“This award is very special and humbling to me. To be recognized for my career work by the institution and department who trained me as a scientist is gratifying. I could not have imagined the career opportunities that would come my way as a result of my mentoring and training at Purdue University.”
- BS, Zoology and Chemistry, University of Arizona, 1968
- MS, Pharmacology and Toxicology, Purdue University, 1972
- PhD, Pharmacology and Toxicology, Purdue University, 1974
- Recipient of both a competitive NIH R01 and National American Heart Association research grant while a faculty member at the University of Nebraska College of Pharmacy and School of Medicine
- Instrumental in the establishment of a graduate research program in Pharmacology and Toxicology at the University of Nebraska College of Pharmacy
- Selection as a National MASUA Honor Lecturer
- Became the first non-physician scientist to become Director within the Worldwide Clinical Drug Development Division of SmithKline Beecham/GlaxoSmithKline Pharmaceuticals
- Holder of multiple Clinical Use patents for Coreg®, a drug used for the treatment of chronic heart failure
Terry Holcslaw received his MS and PhD in Pharmacology and Toxicology from the Purdue College of Pharmacy under the training and mentorship of Dr. Bill Bousquet, which he considers one of his career highlights. He spent the next 12 years as a Pharmacology faculty member at the University of Nebraska College of Pharmacy and School of Medicine. During his tenure, he assumed ranks of increasing importance and responsibility in teaching, cardiovascular research, and administration.
In 1987, Terry moved to the pharmaceutical industry to expand his career becoming involved in clinical drug development. He joined the Clinical Drug Development Division of SmithKline French Laboratories which became SmithKline Beecham Pharmaceuticals and subsequently GlaxoSmithKline Pharmaceuticals. He assumed positions of greater importance and worldwide responsibility over 19 years, rising to Director and Senior Scientist in the Clinical Drug Development Division. He was the first non-physician scientist to be made Director within the Worldwide Clinical Drug Development Division of SmithKline Beecham/GlaxoSmithKline Pharmaceuticals. While involved in leadership roles in successful development of a variety of cardiovascular drugs approved by the Food and Drug Administration, his final 10 years with the company were linked to the highly successful development of Coreg® for treating mild, moderate, and severe chronic heart failure. This drug has been instrumental in saving many lives around the world, and he is most proud of his leadership efforts in contributing to his worldwide team’s success in that regard.
Terry went on to form a new drug development company—New Drug Development Services, Inc.—a contract writing company specializing in preparing clinical documents for pharmaceutical companies as well as clinical research organizations. He is currently Vice President of Business Development at New Drug Development Services, Inc.